The test detected more than 50 cancers at a specificity of 99.3%, across all stages, and identified the tissue of origin (where the cancer is located in the body) with high accuracy when a cancer signal was detected. The low false-positive rate of less than 1% reduces unnecessary anxiety and the costs and medical risks of unneeded follow-up procedures.
